News | RSNA | December 24, 2019

Alzheimer’s Disease AI Research Receives RSNA Margulis Award

The Radiological Society of North America (RSNA) presented its eighth Alexander R. Margulis Award for Scientific Excellence to Jae Ho Sohn, M.D., from the Radiology & Biomedical Imaging Department at the University of California in San Francisco (UCSF)

Jae Ho Sohn, M.D.

December 24, 2019 — The Radiological Society of North America (RSNA) presented its eighth Alexander R. Margulis Award for Scientific Excellence to Jae Ho Sohn, M.D., from the Radiology & Biomedical Imaging Department at the University of California in San Francisco (UCSF), for the article, “A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18F-FDG PET of the Brain,” published online in November 2018. The groundbreaking study shows the significant potential of artificial intelligence (AI) as a diagnostic tool in Alzheimer’s disease (AD). Sohn was presented with the award today at RSNA 2019 in Chicago.

Named for Alexander R. Margulis, M.D., a distinguished investigator and inspiring visionary in the science of radiology, this annual award recognizes the best original scientific article published in RSNA’s peer-reviewed journal Radiology.

A radiology resident with an engineering background,  Sohn co-authored the study with the goal of developing a deep learning algorithm to detect patterns on complex brain images to identify AD as early as possible.

“Alzheimer’s is a costly, devastating disease and by the time a clinical diagnosis is made, it’s often too late,” said Sohn, who leads the UCSF Big Data in Radiology (BDRAD) multidisciplinary team of physicians and engineers focusing on radiological data science. “We hypothesized we could use AI as an early prediction tool for Alzheimer’s in conjunction with other biochemical and imaging tests. If we can detect the disease early enough, physicians have a chance of slowing it down or halting it through therapeutic intervention.”

The results far exceeded Sohn’s expectations. Using 18F fluorodeoxyglucose (FDG) PET scans to train a deep learning algorithm, Sohn and colleagues were able to detect early-stage AD about six years before it was clinically diagnosed.

“This research is groundbreaking,” said Radiology editor David A. Bluemke, M.D. “It demonstrates the potential for state-of-the-art AI technology to help interpret the remarkably complex patterns on FDG PET imaging in patients with Alzheimer's disease. Even more hopeful for Alzheimer’s patients, this same line of research will also apply to more specific PET tracers for detecting the disease.”

The study began when UCSF colleagues Benjamin Franc, M.D., a nuclear medicine specialist, and Youngho Seo, Ph.D., a nuclear medicine physicist, approached Sohn and undergraduate student Yiming Ding about developing an algorithm to interpret FDG PET brain scans. Research has linked the disease process to changes in metabolism, which can be difficult to recognize. PET scans can measure the uptake of FDG in brain cells, indicating metabolic activity.

The research team used data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a major multi-site study focused on clinical trials to improve prevention and treatment of this disease. The ADNI dataset included more than 2,100 FDG PET brain images from 1,002 patients. The researchers trained the deep learning algorithm on 90 percent of the dataset and then tested it on the remaining 10 percent of the dataset.

Finally, they tested the algorithm on an independent set of 40 FDG PET imaging exams from 40 patients that it had never studied. Results showed that algorithm achieved 82 percent specificity and 100 percent sensitivity at detecting the disease an average of more than six years prior to the final diagnosis.

“I was surprised at how high the numbers were, but I already knew AI was going to be more effective than humans,” Sohn said. “The very special nature of AI detects very global, subtle changes that the human eye cannot.”

Sohn, who plans to continue researching the vast capabilities of AI in radiology, was extremely honored to be chosen for Margulis Award, which he believes will open doors for future research.

“I was completely surprised and shocked to receive the award,” Sohn said. “This recognition will pave the way for my research career and will allow me to connect with other researchers doing important work.”

Sohn stresses that further validation with larger and prospective external tests must be performed before the Alzheimer’s detection algorithm can be used clinically. However, he believes that researchers united in the fight against Alzheimer’s are on the brink of a significant breakthrough.

“I really think we are at an inflection point with Alzheimer’s disease,” Sohn said. “I believe we will see major progress in the next decade or two.”

Access the study at https://pubs.rsna.org/doi/10.1148/radiol.2018180958.  

Related content:

Clinical Implementation of Artificial Intelligence in Radiology

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 07, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2  The first of three clinical scenarios presented to the panel with final recommendations. Mild features refer to absence of significant pulmonary dysfunction or damage. Pre-test probability is based upon background prevalence of disease and may be further modified by individual’s exposure risk. The absence of resource constraints corresponds to sufficient availability of personnel, personal protective equipment, COVID-19 testing, hospital beds, and/or ve

 The first of three clinical scenarios presented to the panel with final recommendations. Mild features refer to absence of significant pulmonary dysfunction or damage. Pre-test probability is based upon background prevalence of disease and may be further modified by individual’s exposure risk. The absence of resource constraints corresponds to sufficient availability of personnel, personal protective equipment, COVID-19 testing, hospital beds, and/or ventilators with the need to rapidly triage patients. Contextual detail and considerations for imaging with CXR (chest radiography) versus CT (computed tomography) are presented in the text. (Pos=positive, Neg=negative, Mod=moderate). [Although not covered by this scenario and not shown in the figure, in the presence of significant resources constraints, there is no role for imaging of patients with mild features of COVID-19.] Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | April 07, 2020
April 7, 2020 — A multinational consens...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Chest CT findings of pediatric patients with COVID-19 on transaxial images. (a) Male, 2 months old, 2 days after symptom onset. Patchy ground-glass opacities GGO in the right lower lobe

Chest CT findings of pediatric patients with COVID-19 on transaxial images. Male, 2 months old, 2 days after symptom onset. Patchy ground-glass opacities GGO in the right lower lobe. Image courtesy of Radiology: Cardiothoracic Imaging

News | Coronavirus (COVID-19) | April 06, 2020
April 6, 2020 — Children and teenagers with COVID-19...
A recent study earlier this year in the journal Nature, which included researchers from Google Health London, demonstrated that artificial intelligence (AI) technology outperformed radiologists in diagnosing breast cancer on mammograms
Feature | Breast Imaging | April 06, 2020 | By Samir Parikh
A recent study earlier this year in the journal Nature,
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 U.S. Surgeon General Jerome Adams, M.D., M.Ph demonstrates how the general public can make their own face masks for non-clinical use.

U.S. Surgeon General Jerome Adams, M.D., M.Ph. demonstrates how the general public can make their own face masks for non-clinical use.

News | Coronavirus (COVID-19) | April 04, 2020 | By Melinda Taschetta-Millane
April 4, 2020 — The Centers for Disease Control and Prevention (CDC)
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new